Specialty Pharma Journal Specialty, Precision & Technology
Basel, September 13, 2017 – Novartis announced today, first of its kind Phase III data showing Cosentyx® (secukinumab) delivered high and long-lasting skin clearance in patients with moderate-to-severe plaque psoriasis at 5 years[1]. These data were presented for the first time at the 26th European Academy of Dermatology and Venereology (EADV) Congress in Geneva, …
Tag Archives: Cosentyx
September, 2017
October, 2015
-
5 October
New Promising Tool for Psoriatic Arthritis
Psoriatic arthritis, being slightly less common than rheumatoid arthritis, garners less research than rheumatoid arthritis. However, more than 2 million Americans struggle with the devastating effects of this disease, which causes chronic, painful inflammation of the joints and connective tissue. It’s common for psoriatic arthritis to develop about a decade …